Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Mast cells and eosinophils in mastocytosis, chronic eosinophilic leukemia, and non-clonal disorders.

Gotlib J, Akin C.

Semin Hematol. 2012 Apr;49(2):128-37. doi: 10.1053/j.seminhematol.2012.01.007. Review.

PMID:
22449623
2.

Eosinophilia in mast cell disease.

Kovalszki A, Weller PF.

Immunol Allergy Clin North Am. 2014 May;34(2):357-64. doi: 10.1016/j.iac.2014.01.013. Epub 2014 Mar 13. Review.

3.

The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease.

Yamada Y, Rothenberg ME, Lee AW, Akei HS, Brandt EB, Williams DA, Cancelas JA.

Blood. 2006 May 15;107(10):4071-9. Epub 2006 Jan 17.

4.

KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significance.

Schwaab J, Umbach R, Metzgeroth G, Naumann N, Jawhar M, Sotlar K, Horny HP, Gaiser T, Hofmann WK, Schnittger S, Cross NC, Fabarius A, Reiter A.

Am J Hematol. 2015 Sep;90(9):774-7. doi: 10.1002/ajh.24075. Epub 2015 Aug 14.

5.

KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities.

Maric I, Robyn J, Metcalfe DD, Fay MP, Carter M, Wilson T, Fu W, Stoddard J, Scott L, Hartsell M, Kirshenbaum A, Akin C, Nutman TB, Noel P, Klion AD.

J Allergy Clin Immunol. 2007 Sep;120(3):680-7. Epub 2007 Jul 12.

PMID:
17628645
6.

The severity of FIP1L1-PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus.

Burgstaller S, Kreil S, Waghorn K, Metzgeroth G, Preudhomme C, Zoi K, White H, Cilloni D, Zoi C, Brito-Babapulle F, Walz C, Reiter A, Cross NC.

Leukemia. 2007 Dec;21(12):2428-32. Epub 2007 Oct 4.

PMID:
17914408
7.

FIP1L1-PDGFRalpha imposes eosinophil lineage commitment on hematopoietic stem/progenitor cells.

Fukushima K, Matsumura I, Ezoe S, Tokunaga M, Yasumi M, Satoh Y, Shibayama H, Tanaka H, Iwama A, Kanakura Y.

J Biol Chem. 2009 Mar 20;284(12):7719-32. doi: 10.1074/jbc.M807489200. Epub 2009 Jan 14.

8.

FIP1L1/PDGFRalpha synergizes with SCF to induce systemic mastocytosis in a murine model of chronic eosinophilic leukemia/hypereosinophilic syndrome.

Yamada Y, Sanchez-Aguilera A, Brandt EB, McBride M, Al-Moamen NJ, Finkelman FD, Williams DA, Cancelas JA, Rothenberg ME.

Blood. 2008 Sep 15;112(6):2500-7. doi: 10.1182/blood-2007-11-126268. Epub 2008 Jun 6.

9.

FIP1L1-PDGFRA and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia.

Tefferi A, Lasho TL, Brockman SR, Elliott MA, Dispenzieri A, Pardanani A.

Haematologica. 2004 Jul;89(7):871-3.

10.

Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA.

Sadovnik I, Lierman E, Peter B, Herrmann H, Suppan V, Stefanzl G, Haas O, Lion T, Pickl W, Cools J, Vandenberghe P, Valent P.

Exp Hematol. 2014 Apr;42(4):282-293.e4. doi: 10.1016/j.exphem.2013.12.007. Epub 2014 Jan 6.

11.

[Mastocytosis and eosinophilic leukemia: diagnostics and classification].

Sotlar K, Valent P, Horny HP.

Pathologe. 2012 Nov;33(6):539-52. doi: 10.1007/s00292-012-1654-0. German.

PMID:
23085697
12.

CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.

Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM, Reeder TL, Li CY, Cross NC, Cools J, Gilliland DG, Dewald GW, Tefferi A.

Blood. 2003 Nov 1;102(9):3093-6. Epub 2003 Jul 3.

13.

Mastocytosis.

Metcalfe DD.

Novartis Found Symp. 2005;271:232-42; discussion 242-9. Review.

PMID:
16605139
14.

FIP1L1/PDGFR alpha-associated systemic mastocytosis.

Yamada Y, Cancelas JA.

Int Arch Allergy Immunol. 2010;152 Suppl 1:101-5. doi: 10.1159/000312134. Epub 2010 Jun 4. Review.

15.

The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia.

Cools J, Stover EH, Wlodarska I, Marynen P, Gilliland DG.

Curr Opin Hematol. 2004 Jan;11(1):51-7. Review.

PMID:
14676627
16.

Molecular classification and pathogenesis of eosinophilic disorders: 2005 update.

Gotlib J.

Acta Haematol. 2005;114(1):7-25. Review.

PMID:
15995322
17.

Synchronous FIP1L1-PDGFRA-positive chronic eosinophilic leukemia and T-cell lymphoblastic lymphoma: a bilineal clonal malignancy.

Capovilla M, Cayuela JM, Bilhou-Nabera C, Gardin C, Letestu R, Baran-Marzak F, Fenaux P, Martin A.

Eur J Haematol. 2008 Jan;80(1):81-6. Epub 2007 Nov 19.

PMID:
18028420
19.

FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells.

Crescenzi B, Chase A, Starza RL, Beacci D, Rosti V, Gallì A, Specchia G, Martelli MF, Vandenberghe P, Cools J, Jones AV, Cross NC, Marynen P, Mecucci C.

Leukemia. 2007 Mar;21(3):397-402. Epub 2007 Jan 11.

PMID:
17215855
20.

Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib.

Florian S, Esterbauer H, Binder T, Müllauer L, Haas OA, Sperr WR, Sillaber C, Valent P.

Leuk Res. 2006 Sep;30(9):1201-5. Epub 2006 Jan 6.

PMID:
16406018

Supplemental Content

Support Center